p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target

Author(s): Hui Jing, Lu-Lu Wei, Fu-Chun Huo, Xin Ren, Jun-Nian Zheng*, Dong-Sheng Pei*.

Journal Name: Letters in Drug Design & Discovery

Volume 14 , Issue 10 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: To explore the function of p42.3 in gastric carcinoma.

Methods: We summarized the intricate regulation of p42.3 in gastric carcinoma from several aspects, namely, the structure features, the expression level, its regulation on cell cycle and EMT, its relationship with miR-29a as well as the optimal feedback circuit involved in.

Results: We addressed the complex functions of p42.3 in regulating EMT, migration, invasion, proliferation and the optimal regulation network in GC, as well as the significant up/down-stream signal molecules involved in the pathway. We have also illuminated that miR-29a can inhibit cell proliferation and block the cell cycle, at least in part, via the repression of p42.3.

Conclusion: In short, p42.3 might serve as a potential therapeutic target in the treatment of GC.

Keywords: p42.3, gastric carcinoma, cell cycle, EMT, miR-29a, therapeutic target.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 10
Year: 2017
Page: [1221 - 1225]
Pages: 5
DOI: 10.2174/1570180814666170306121357
Price: $58

Article Metrics

PDF: 17
HTML: 1